Welcome to the First Quarter 2016 Harvard Bioscience Incorporated Earnings Conference Call. My name is Ellen and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later we will conduct a question and answer session. [Operator Instructions] Please note that this conference is being recorded. I will now turn the call over to Corey Manchester, Director of Finance and Investor Relations. Mr. Manchester, you may begin.

Thank you, Ellen and good morning everyone. Thank you for joining us for the Harvard Bioscience first quarter 2016 earnings conference call. Leading the call today will be Jeffrey Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Before I turn the call over to Jeff, I will read our Safe Harbor statement. In our discussion today, we make may make statements that constitute forward-looking statements. Our actual results and performance may differ materially from what we have projected due to risks and uncertainties, including those detailed in our Annual Report on Form 10-K for the period ended December 31, 2015, and our other public filings. Any forward-looking statements, including those related to the Company's future results and activities represent our estimates as of today and should not be relied upon as representing our estimates as of any subsequent day. I will now turn the call over to Jeff Duchemin. Jeff, please go ahead.

Thank you, Corey. Good morning, everyone. Thank you for joining us for our first quarter 2016 conference call. In my discussion today, I will begin by providing some brief comments on our fourth quarter and full year 2015 since we did not hold a conference call to discuss those results followed by a discussion of our first quarter 2016 results. Our CFO, Robert Gagnon will then provide more financial details related to our first quarter 2016 results and our 2016 guidance. As most of you are aware 2015 was an important year of investment for Harvard Bioscience. We started the year with the acquisition of HEKA Electronic which added to our industry leading portfolio of electrophysiology companies. During the year, we launched the first phase of a common ERP system and we finished the year having successfully consolidated five facilities. The tremendous effort by our team to accomplish these initiatives in one year is a testament to the team we've assembled at Harvard Bioscience. 2015 was not without its challenges. As we've discussed, foreign currency was a significant headwind in 2015 as was GE Healthcare's decision to discontinue the sale of it spectrophotometer brands. We also spent a significant amount of time and effort over the last two months working to finalize our full year 2015 financial close and audit following the identification of an embezzlement and its concealment at our Denville subsidiary. As reported a few weeks ago, the investigation and audit are closed. Moving to our first quarter 2016 results. We reported a solid quarter with both topline and bottomline growth over last year's first quarter. Revenues for the quarter were $27 million approximately 5% higher than last year's first quarter. Excluding currency translation, our revenues grew 6% compared to last year's Q1. Non-GAAP EPS was $0.05 up…

Thanks Jeff. Before I begin to discuss Q1, I’d like to briefly address the topic of the embezzlement and subsequent forensic investigation. This was an unfortunate situation and we are relieved to be putting it behind us. The total cash embezzled was less than $50,000 and while this episode only impacted a small group of people, they put forth a tremendous effort to complete the forensic investigation, as well as complete the year-end financial reporting process. I’d like to acknowledge that group and thank them for their efforts. Also, as discussed in the recent annual report on Form 10-K, the company reported weaknesses and internal controls and infuriation related to our remediation plan. We are working diligently to resolve these issues. Now turning to Q1. As in previous quarters, much of my focus will be on non-GAAP quarterly results which we believe better represents the ongoing economics of the business, reflects how we set and measure our incentive compensation plans, and how we manage the business internally. However, I will briefly review the GAAP results, the differences of which are outlined in the earnings release we issued today which can be found on our website under press releases. Also, new this quarter, we have included a comparative non-GAAP quarterly income statement as Exhibit 10 to the press release. Additionally, any material financial or other statistical information presented on the call which is not included in our press release will be archived and available in the Investor Relations section of our website. And the replay of this call will also be available for one week at the same location on our website at harvardbioscience.com. So now beginning with the topline, revenues in the first quarter were $27 million, an increase of $1.2 million or 5% compared with revenues of $25.8 million…

[Operator Instructions] Our first question is from Paul Knight with Janney Montgomery.

Hi guys. On the Q4 bookings you mentioned, what product lines was that and why wouldn't you expect to see that type of - why wouldn't you expect to see this type of organic growth the rest of the year, is my first question?

Paul some of the - this is Jeff, good morning. Some of the products that were part of that booking - a large booking in Q4 were more of timing. If you look at China, we’ll talk a little bit about China here for a second, we had significant growth in Q1 in China about 30% growth, more timing related with AAAs which is amino acid analyzer product are being sold into China. We don't expect that to repeat in Q2. We’ll continue to sell product during the year, but we won’t see the significant number of units that were sold in Q1 transitioning to a future quarters. So more of a timing related topic with China and with other AAA units that were sold there from a booking standpoint.

Okay. And then on the operating margin, again, is that - it seems like you are implying kind of moderate to flat levels the rest of the year. Is that because of this boost in orders you had, or what's your thought on Op margin for FY16?

It’s Rob, if you take the midpoint of the guidance which is $0.18 multiply it out to $35 million shares, assume a 30% tax rate, the operating margin based on the guidance is around 9%. So it's right with what we reported for the first quarter. But I think your point is right on and I'd also add the fact that we had 190 bip improvement on gross margin was a bit ahead of what we had expected. And I think there's probably some timing there through the rest of the year, but nonetheless we're still seeing the improvements in gross margin because of those consolidations.

And the third question is, the academic market. We would hope gets better. Are you seeing any comment? Are you hearing any comments? Seeing anything in terms of orders, even post Q1?

I think Paul this year in Q1 compared to last year we're seeing a much more stable academic market on a global basis specifically in Europe. We're happy with the results that we've achieved in Q1 in the U.S. What I've read, what I'm hearing is that as the year transitions, the increase in that NIH budget will hopefully funnel into buying habits of our customers. So we expect the back half of the year to be stronger than the first half of the year. But right now we see a stable academic market. I still believe it's in the 1% to 2% growth range. I think majority of the growth in the industry is coming from biopharma, which is a small percentage of our business. But I would say the back half of the year should be some tailwinds for us.

Okay. And then and then lastly, Rob, could you talk about balance sheet, where you are with your debt due, credit line et cetera?

Yes absolutely. So we amended the facility it was disclosed in the 10-K that we filed a few weeks ago, but we amended that facility in the first quarter. And it was an amendment to change the amortization of the principal payments, so historically it's been $5 million a year it's been reduced to $2.5 million a year. Hence we have at the moment, we have a line of credit available which will grow over the course of the year we're expecting that June 30 that number will be high single digits it’s available and throughout the year it will expand into the teens. So we're feeling pretty good about where we are right now with the credit facility and the line of credit. Q – Paul Knight: Okay. Thanks guys.

[Operator Instructions] The next question is from Raymond Myers with Benchmark.

Thank you for the clarity of the remarks this morning. It was very helpful. Jeff, your remarks suggest that the margin expansion here in Q1 might be just the first benefit of your consolidation plan. Can you describe the next stages of your plans and how much more improvement might be in store?

Yes, I mean it was a great deal of work done last year with five sites being consolidated in one year. I mean it's an incredible accomplishment for the organization. I think we're starting to see the benefit as we posted today. The benefit will continue and it will continue in many aspects of the business. I think we're going to become more efficient in terms of building products, I think we're going to reduce inventories. We're going to be able to increase our service levels to customers. So the consolidation efforts of last year, I think will continue not only in 2016, but beyond in terms of our ability to produce high quality products and service our customers better than this company ever has.

That's great. And then next maybe for Rob. Help me to translate some of this to the income statement. The non-GAAP G&A expense that you reported this quarter was under $4.2 million. That looks like a big reduction from last year. But once the investigation charges ended, can you help us understand what level of quarterly G&A expense we would expect going forward?

Sure. Just so, it's clear. The non-GAAP G&A number excludes those forensic investigation costs. So we reported today a $4.2 million in the third quarter of 2016 which is right in line with what we reported on a non-GAAP basis for the first quarter last year. And I think that that's a pretty good run rate number to be thinking about. There is clearly going to be some ups and downs throughout the year. But I think that's probably in line with our expectations throughout 2016. Is that helpful?

That helps, yes that definitely does, thanks. I want to touch on the GE spectrophotometer business. Jeff, you said that, that business is meeting your expectations. That's helpful, but could you give us a sense of what are your goals and expectations for this business?

Yes, I mean, over the last 3 or 4 months ending 2015 we had a transitional service agreement in place with GE, we had a plan in place, we had a team working on that. What we've been able to do is make contact with all of GE's spectrophotometer dealers on a global basis. We have direct agreements with these companies. We have hired both sales and service individuals to represent this product category for us. We monitor this on a weekly basis, both sales and service, and at this point in time as I said in my comments, we're right where we need to be at this point in the year, so we're very happy with the transition and the performance of our new distribution partners on a global basis.

Thanks. And you mentioned in your remarks that the MCS and TBSI businesses were showing a meaningful gains. Could you elaborate on that? That sounded interesting.

Yes, so I didn't touch base on the particular products they're working on, but there is some exciting technology and innovation being developed at both MCS and Triangle BioSystems. I'll start with Triangle BioSystems. They received a DARPA grant and I’m not sure you can understand or know what DARPA is, but DARPA stands for Defense Advanced Research Project Agency and basically it’s a funding agency, it's part of the Department of Defense and we were granted an award to develop some technology, technology that we will have the rights too. We will own the patents too. And basically we're developing three specific systems, one is an electrical stimulator system, the second is an optogenetic stimulator system, and the third is a neural recording system. And the interesting thing about this is, yes the technology and science itself related to brain, brain research, optogenetics is a very exciting and progressive area of science and we're in the forefront of that with our electrophysiology acquisitions and legacy business as a part of Harvard Bioscience. So we're really excited about that. On the MCS side, they are also working on some new technology. I don't want to elaborate too much because the products haven’t been launched yet, but they also are coming out with some stimulator systems or recording systems that will progress their baseline of current products. So we are excited about that. And one other thing too, I think we mentioned probably post Q2, our animal physiology business is coming out with a physiological monitoring system, and we are excited about this, we'll be launching this and we will be discussing it post Q2.

That sounds encouraging. You described a number of new products that have been developed internally at Harvard. That sounds like a new growth driver going forward that really had not been a focus of Harvard in the past with respect to internally developed new products. Is that a fair statement?

Ray, going back 2.5 years ago when I started in the new management team which developed, and we changed our strategy, one of the elements of our strategy was reinvigorating product development. So it's been around for a couple of years and there is many phases of product development. There is new products, there is breakthrough technologies, there is product line extensions. We’ve been working on all of these for the last 2.5 years. Most of it is continued improvement, continued maintenance of current legacy products. We’re now at the point where we are starting to work on innovation. The exciting part of these acquisition that we’ve made and the benefit they bring to our business, not only do they bring a revenue source, but they bring some very talented individuals, research and development individuals that can help innovate and transition Harvard Bioscience not only into a just a manufacturing company but global innovation company. So we are excited about where we are. It's been a project, it's been a place or process has been in place for couple of years now, but we are getting to the point where we are going to start to launch new products and hopefully we’ll be talking about in the upcoming quarters.

That's great. I just have two more. First housekeeping, Rob maybe if you could tell us what were backlog in bookings? And then Jeff, maybe finish up with discussion of what you see as opportunities for further accretive acquisitions? Thank you, guys.

Ray, bookings were just over 26 million and on a currency adjusted basis they are relatively flat year-over-year. We’ve finished with 8 million of backlog. And just to note, reflected in the book and also in the backlog is the fact that the spectrophotometer business is back but it's building back and as I mentioned in my prepared remarks, it was unfavorable $0.5 million in the quarter in terms of sales.

Great. Thanks Rob.

And really the back half of your question on acquisition, acquisitions continue to be an element of our strategy, but I will tell you, the focus right now here at Harvard Bioscience is top line growth. Really everything we are doing from a business standpoint is working with our global commercial organizations to drive the topline. That's the number one goal of this business this year. And I think we started out the year on the right foot, we want to continue it moving forward. And the focus is there right now in terms of topline growth.

Great. Thanks for all your comments. Appreciate it.

We have no further questions at this time. I’d like to turn the call back over to Jeff Duchemin for closing remarks.

Thanks Ellen. I’d like to thank our shareholders and employees for your continued support. We truly appreciate it. We look forward to speaking again to all of you after Q2. Have a good day everyone. Thank you.

Thank you. Ladies and gentlemen this concludes today's conference. Thank you for participating. You may now disconnect.